Takeda Offers $2.4bn No-Fault Settlement Of Actos Suits
This article was originally published in PharmAsia News
Following rumors a few weeks ago, Takeda has now formally agreed to settle most of the U.S. product lawsuits relating to its diabetes drug Actos, for a total of around $2.4 billion but with no admission of liability, in a move that will see the firm post a full-year loss.
You may also be interested in...
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.
Since Ramona Sequeira was made president of Takeda's US business a year ago, she has set out a new strategy that she hopes will add to the turnaround of the Japanese major after a difficult patch in its history.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.